Physician profile
Simon Sy Tan
NPI 1811001365
$16,856.65
in general payments reported to CMS, 2019-2025
69 companies · $2,557 in 2025
The $2,557 reported for 2025 was more than what 76% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,486 · 2020: $1,793 · 2021: $2,990 · 2022: $3,037 · 2023: $1,954 · 2024: $2,039 · 2025: $2,557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,550.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,549.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,645.04 | 2019-2025 | Ubrelvy, Duopa, Botox |
| Genentech USA, INC. | $1,014.10 | 2019-2025 | Enspryng, Ocrevus, Ocrevus Zunovo |
| Emd Serono, INC. | $1,012.55 | 2019-2025 | Mavenclad |
| Biogen, INC. | $944.06 | 2019-2025 | Vumerity, Leqembi, Tysabri |
| Sk Life Science, INC. | $879.50 | 2020-2025 | Xcopri |
| Novartis Pharmaceuticals Corporation | $677.12 | 2019-2025 | |
| Lundbeck LLC | $672.33 | 2019-2025 | Vyepti, Rexulti |
| Ucb, INC. | $655.80 | 2019-2025 | Briviact, Rystiggo |
| Eisai INC. | $641.46 | 2019-2025 | |
| Allergan, INC. | $539.36 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $518.75 | 2024-2025 | Ponvory |
| Lilly USA, LLC | $445.66 | 2019-2024 | Amyvid, Emgality, Kisunla |
| Impel Pharmaceuticals INC. | $385.06 | 2022-2023 | Trudhesa |
| Teva Pharmaceuticals USA, INC. | $365.59 | 2019-2024 | Ajovy |
| Alnylam Pharmaceuticals INC. | $351.51 | 2019-2025 | Onpattro, Amvuttra |
Show all 69 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $342.26 | 2021-2025 | |
| Amgen INC. | $324.02 | 2019-2025 | Uplizna |
| Alexion Pharmaceuticals, INC. | $302.76 | 2019-2024 | Ultomiris |
| Biohaven Pharmaceuticals, INC. | $287.30 | 2021 | |
| Avanir Pharmaceuticals, INC. | $265.08 | 2019-2022 | |
| Upsher-Smith Laboratories LLC | $260.15 | 2020-2023 | |
| Amneal Pharmaceuticals LLC | $242.51 | 2019-2025 | Crexont, Ongentys, Ongentys 50mg Capsules 30 |
| Kyowa Kirin, INC. | $240.59 | 2019-2024 | Nourianz |
| Genzyme Corporation | $231.71 | 2019-2023 | |
| Supernus Pharmaceuticals, INC. | $219.66 | 2019-2025 | Qelbree |
| Mallinckrodt Enterprises LLC | $212.43 | 2019 | |
| Grifols USA, LLC | $210.06 | 2019-2025 | Gamunex-C |
| Azurity Pharmaceuticals, INC. | $199.57 | 2023-2025 | Horizant, Horizant |
| Argenx US, INC. | $186.22 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Biohaven Pharmaceutical Holding Company LTD. | $182.56 | 2022 | |
| Csl Behring | $170.87 | 2019-2025 | Hizentra |
| Otsuka America Pharmaceutical, INC. | $148.40 | 2023-2025 | Nuedexta, Rexulti |
| Janssen Pharmaceuticals, INC | $138.91 | 2022-2023 | Ponvory |
| Celgene Corporation | $117.46 | 2021-2024 | Zeposia |
| Merz North America, INC. | $116.29 | 2019-2020 | |
| Corium, LLC | $114.63 | 2022-2023 | Adlarity |
| Arbor Pharmaceuticals, INC. | $114.30 | 2019-2022 | |
| Aquestive Therapeutics, INC. | $106.18 | 2019-2021 | |
| Axsome Therapeutics, INC. | $89.34 | 2025 | Symbravo |
| Curonix LLC | $84.71 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Mdd US Operations, LLC | $71.43 | 2019 | |
| Octapharma USA, INC. | $70.92 | 2022-2025 | Panzyga |
| Banner Life Sciences, LLC | $69.90 | 2022 | |
| Collegium Pharmaceutical, INC. | $67.55 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $65.81 | 2022-2024 | Hyqvia |
| Horizon Therapeutics Plc | $65.66 | 2022-2023 | Uplizna |
| Merz Pharmaceuticals, LLC | $57.39 | 2021 | |
| Assertio Therapeutics, INC. | $57.31 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $56.82 | 2021 | |
| Almatica Pharma LLC | $56.24 | 2021 | |
| Ge Healthcare | $55.11 | 2020-2024 | |
| Adamas Pharmaceuticals, INC. | $48.71 | 2020 | |
| Abbott Laboratories | $47.09 | 2021-2025 | Jot Dx, Infinity |
| Tonix Medicines, INC. | $44.69 | 2025 | Zembrace Symtouch |
| Zogenix INC. | $35.30 | 2021 | |
| Tanabe Pharma America, INC. | $33.61 | 2021-2022 | |
| Promius Pharma LLC | $32.93 | 2019 | |
| Cala Health, INC. | $31.50 | 2023 | Cala Trio |
| Boston Scientific Corporation | $30.71 | 2023 | |
| Currax Pharmaceuticals LLC | $27.69 | 2020 | |
| Impel Pharmaceuticals LLC | $24.53 | 2025 | Trudhesa |
| Ipsen Biopharmaceuticals, INC | $23.71 | 2021 | |
| Sunovion Pharmaceuticals INC. | $21.75 | 2019 | |
| Endo Pharmaceuticals INC. | $21.36 | 2020 | |
| Springworks Therapeutics, INC. | $20.00 | 2025 | Gomekli |
| Greenwich Biosciences, INC. | $18.53 | 2021 | |
| Avion Pharmaceuticals | $15.64 | 2023 | Dhivy |
| Kedrion Biopharma, INC. | $15.26 | 2024 | Rhogam Ultra-Filtered Plus, Albuked, Gammaked |
| Acorda Therapeutics, INC | $13.64 | 2023 | Inbrija |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simon Tan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.